Fig. 2From: The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemiaClonogenic growth inhibition of primary MDS and AML specimens. LDE225 (erismodegib) and 5-azacytidine in primary patient samples. UT untreated. Dose of 5-Aza and LDE225 given in micromolar at y-axis. Percent growth at x-axisBack to article page